drugset / Trial / NCT03660787

Efficacy and Dose Ranging Study of Seroguard

NCT03660787 ↗

Phase 2 Completed 114 enrolled Pharmasyntez Cromos Pharma LLC · collab
RandomizedParallel-groupDouble-blindPrevention

Summary

This trial was a multi-center, double-blind, randomized, parallel group, placebo-controlled, phase II study in adult hospitalized female patients with the confirmed diagnosis of pelvic adhesive disease in Study centres in Russia.

Timeline

Start
2017-05-04
Primary completion
2018-01-23
Completion
2018-01-23

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Seroguard Unknown 1.5 unknown Other
Subject Seroguard Unknown 2.4 unknown Other

Indications

No indication recorded.